Introduction
Vical’s main focus is to research and develop vaccines and novel therapeutics based on its core DNA delivery technology for the treatment of wide range of diseases in the areas of infectious and cancer related diseases. It has leveraged its patented technologies through licensing and collaboration agreements with other pharmaceutical companies to discover and develop respective product candidates
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Vical's product focus is the development of infectious disease vaccines and cancer immunotherapeutics. The company’s current independent development focus is on the novel DNA vaccines for cytomegalovirus (CMV) and its cancer immunotherapeutics Allovectin-7 and IL-2/EP, as well as other preclinical targets such as influenza. Vical derives its revenues from collaboration and licensing agreements. These revenues are related to collaborative research and development agreements (CRADA) with various government institutions such as NIH (National Institutes of Health), CDC (The US Centers for Disease Control and Prevention) and other government and research institutions. Vical’s sole contributor to sales growth out to 2010 will be royalties, licenses, collaboration and other revenues during the period 2006-2010. Revenues from this stream are expected to increase at a CAGR of 9%, from $15 million in 2006 to $20 million in 2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization .
Report Highlights
[Studien Infos ausblenden]
